235 related articles for article (PubMed ID: 20384577)
1. Tyrosine kinase inhibitors.
Natoli C; Perrucci B; Perrotti F; Falchi L; Iacobelli S;
Curr Cancer Drug Targets; 2010 Aug; 10(5):462-83. PubMed ID: 20384577
[TBL] [Abstract][Full Text] [Related]
2. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
Hojjat-Farsangi M
J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
[TBL] [Abstract][Full Text] [Related]
3. Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural models.
Crespan E; Zucca E; Maga G
Curr Med Chem; 2011; 18(19):2836-47. PubMed ID: 21651495
[TBL] [Abstract][Full Text] [Related]
4. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
Steeghs N; Nortier JW; Gelderblom H
Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
[TBL] [Abstract][Full Text] [Related]
5. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase blockers: new hope for successful cancer therapy.
Pytel D; Sliwinski T; Poplawski T; Ferriola D; Majsterek I
Anticancer Agents Med Chem; 2009 Jan; 9(1):66-76. PubMed ID: 19149483
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
Huang L; Jiang S; Shi Y
J Hematol Oncol; 2020 Oct; 13(1):143. PubMed ID: 33109256
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.
Zhao Y; Bilal M; Raza A; Khan MI; Mehmood S; Hayat U; Hassan STS; Iqbal HMN
Int J Biol Macromol; 2021 Jan; 168():22-37. PubMed ID: 33290765
[TBL] [Abstract][Full Text] [Related]
9. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
10. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis.
Murugesan S; Murugesan J; Palaniappan S; Palaniappan S; Murugan T; Siddiqui SS; Loganathan S
Curr Cancer Drug Targets; 2021; 21(1):55-69. PubMed ID: 33038912
[TBL] [Abstract][Full Text] [Related]
12. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.
Anreddy N; Gupta P; Kathawala RJ; Patel A; Wurpel JN; Chen ZS
Molecules; 2014 Sep; 19(9):13848-77. PubMed ID: 25191874
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink KJ; Verheul HM
Angiogenesis; 2010 Mar; 13(1):1-14. PubMed ID: 20012482
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapies in chronic myeloid leukemia.
Gora-Tybor J
Curr Cancer Drug Targets; 2012 Jun; 12(5):458-70. PubMed ID: 22483154
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for chronic myeloid leukemia.
Cilloni D; Messa E; Rotolo A; Saglio G
Expert Opin Emerg Drugs; 2010 Jun; 15(2):175-84. PubMed ID: 20201747
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.
Tibes R; Trent J; Kurzrock R
Annu Rev Pharmacol Toxicol; 2005; 45():357-84. PubMed ID: 15822181
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.
Ranieri G; Pantaleo M; Piccinno M; Roncetti M; Mutinati M; Marech I; Patruno R; Rizzo A; Sciorsci RL
Crit Rev Oncol Hematol; 2013 Nov; 88(2):293-308. PubMed ID: 23768779
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.
Shukla S; Chen ZS; Ambudkar SV
Drug Resist Updat; 2012; 15(1-2):70-80. PubMed ID: 22325423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
